Core Insights - U.S. researchers are identifying clinical characteristics that differentiate "super responders" to GLP-1 weight-loss drugs like Wegovy and Zepbound from those who experience only moderate weight loss [1] Group 1 - The research focuses on understanding the specific traits of patients who achieve significant weight loss with GLP-1 medications [1] - The findings aim to enhance the effectiveness of weight-loss treatments by tailoring approaches to individual patient profiles [1]